The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 6.24 — safe zoneOK
- Earnings quality 68/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Alkermes plc. reports it. History and quarterly detail are in the app.
- Product$1.2B
- Vivitrol$467.9M
- Aristada And Aristada Initio$370.0M
- LYBALVI$346.7M
- Manufactured Product And Royalty$291.3M
Leadership changes
From Alkermes plc.'s own filings, the day they're filed.
- Blair C. Jackson · Chief Operating Officer · departureeff. 2026-08-01
- Joshua Reed · Chief Financial Officer · appointmenteff. 2025-09-15
- Frank Anders Wilson · Director · appointmenteff. 2023-12-08
Latest filings
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-12
- 8-K · Company announcement2026-05-05
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Alkermes plc., every answer cited🔒
- The Intelligence Brief — added when Alkermes plc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.